As the 2019 Novel Coronavirus (COVID-19) continues to spread across the world, the challenges for companies operating in the healthcare and life sciences sector are increasing. The EMEA Healthcare Industry Group has prepared a checklist of the new risks emerging for companies operating in the healthcare and life sciences sector as a result of the outbreak.

This document looks at general issues, such as

  • employment law
  • compliance risks
  • contractual liabilities
  • insurance
  • impact on the supply chain
  • tax matters
  • risk disclosures

and also at healthcare specific issues, such as

  • shortages of medicines, medical devices and biocides
  • competition law, IP law-related matters as a result of the disruptions caused by the outbreak
  • impact on clinical trials
  • consequences for digital health
  • effects on market access of medicines
  • joint procurement actions

Explore More Insight